small nuclear ribonucleoprotein polypeptide B2Genealiases: Msl1 · U2B''
Q-omics provides the consensus-scored SNRPB2 profile across patient tissues and cancer cell-line models. SNRPB2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SNRPB2 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, SNRPB2 protein abundance shows 30,213 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, HNSC, and GBM as cancer lineages where SNRPB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNRPB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNRPB2 survival associations across molecular data types. SNRPB2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNRPB2 RNA expression–survival associations across cancer types. High SNRPB2 expression shows unfavorable associations in LIHC, KIRP, HNSC, MESO, SCLC and KICH. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SNRPB2 RNA expression.
This table summarizes SNRPB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SNRPB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNRPB2 shows higher tumor expression in HNSC, KIRC, BLCA, COAD, LIHC and STAD. The HNSC box plot shows higher SNRPB2 RNA expression in tumor versus normal tissue (log2 FC = +0.935, t-test p < 0.001).
This table shows molecular features associated with SNRPB2 in patient tissues and cancer cell lines. In patient samples, SNRPB2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SNRPB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LIVER.
